Trial · NCT02411656
Adverse events84
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 84
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Pembrolizumab) | 6 | 45 | |
| other | Alanine aminotransferase increased | Investigations | Treatment (Pembrolizumab) | 5 | 45 | |
| other | Alkaline phosphatase increased | Investigations | Treatment (Pembrolizumab) | 6 | 45 | |
| other | Allergic rhinitis | Respiratory, thoracic and mediastinal disorders | Treatment (Pembrolizumab) | 4 | 45 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Treatment (Pembrolizumab) | 4 | 45 | |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Pembrolizumab) | 4 | 45 | |
| other | Anxiety | Psychiatric disorders | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Treatment (Pembrolizumab) | 10 | 45 | |
| other | Aspartate aminotransferase increased | Investigations | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment (Pembrolizumab) | 5 | 45 | |
| other | Breast pain | Reproductive system and breast disorders | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Bruising | Injury, poisoning and procedural complications | Treatment (Pembrolizumab) | 4 | 45 | |
| other | Heart Rate increased | Cardiac disorders | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Chest wall pain | Musculoskeletal and connective tissue disorders | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Chills | General disorders | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Constipation | Gastrointestinal disorders | Treatment (Pembrolizumab) | 11 | 45 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment (Pembrolizumab) | 15 | 45 | |
| other | Creatinine increased | Investigations | Treatment (Pembrolizumab) | 3 | 45 | |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Pembrolizumab) | 13 | 45 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02411656/events